NYSE:TFX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. More Details


Snowflake Analysis

Moderate growth potential with questionable track record.


Similar Companies

Share Price & News

How has Teleflex's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TFX is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: TFX's weekly volatility (3%) has been stable over the past year.


Market Performance


7 Day Return

4.4%

TFX

-0.001%

US Medical Equipment

-0.7%

US Market


1 Year Return

14.2%

TFX

36.3%

US Medical Equipment

36.6%

US Market

Return vs Industry: TFX underperformed the US Medical Equipment industry which returned 35.8% over the past year.

Return vs Market: TFX underperformed the US Market which returned 36.5% over the past year.


Shareholder returns

TFXIndustryMarket
7 Day4.4%-0.001%-0.7%
30 Day6.9%1.4%4.3%
90 Day6.1%7.2%8.1%
1 Year14.5%14.2%37.4%36.3%39.6%36.6%
3 Year63.1%61.1%74.7%70.4%53.5%43.7%
5 Year183.9%176.5%157.8%139.2%123.7%98.8%

Long-Term Price Volatility Vs. Market

How volatile is Teleflex's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Teleflex undervalued compared to its fair value and its price relative to the market?

55.89x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: TFX ($403.68) is trading above our estimate of fair value ($382.98)

Significantly Below Fair Value: TFX is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: TFX is poor value based on its PE Ratio (55.9x) compared to the US Medical Equipment industry average (55.1x).

PE vs Market: TFX is poor value based on its PE Ratio (55.9x) compared to the US market (21.2x).


Price to Earnings Growth Ratio

PEG Ratio: TFX is poor value based on its PEG Ratio (2.1x)


Price to Book Ratio

PB vs Industry: TFX is overvalued based on its PB Ratio (5.6x) compared to the US Medical Equipment industry average (5.2x).


Next Steps

Future Growth

How is Teleflex forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

26.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TFX's forecast earnings growth (26.8% per year) is above the savings rate (2%).

Earnings vs Market: TFX's earnings (26.8% per year) are forecast to grow faster than the US market (20% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: TFX's revenue (7.3% per year) is forecast to grow slower than the US market (10.4% per year).

High Growth Revenue: TFX's revenue (7.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TFX's Return on Equity is forecast to be low in 3 years time (10.4%).


Next Steps

Past Performance

How has Teleflex performed over the past 5 years?

15.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TFX has high quality earnings.

Growing Profit Margin: TFX's current net profit margins (13.2%) are lower than last year (17.8%).


Past Earnings Growth Analysis

Earnings Trend: TFX's earnings have grown by 15.3% per year over the past 5 years.

Accelerating Growth: TFX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: TFX had negative earnings growth (-27.5%) over the past year, making it difficult to compare to the Medical Equipment industry average (9.8%).


Return on Equity

High ROE: TFX's Return on Equity (10.1%) is considered low.


Next Steps

Financial Health

How is Teleflex's financial position?


Financial Position Analysis

Short Term Liabilities: TFX's short term assets ($1.4B) exceed its short term liabilities ($540.0M).

Long Term Liabilities: TFX's short term assets ($1.4B) do not cover its long term liabilities ($3.3B).


Debt to Equity History and Analysis

Debt Level: TFX's debt to equity ratio (75.3%) is considered high.

Reducing Debt: TFX's debt to equity ratio has increased from 52.6% to 75.3% over the past 5 years.

Debt Coverage: TFX's debt is not well covered by operating cash flow (17.4%).

Interest Coverage: TFX's interest payments on its debt are well covered by EBIT (6.6x coverage).


Balance Sheet


Next Steps

Dividend

What is Teleflex current dividend yield, its reliability and sustainability?

0.34%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: TFX's dividend (0.34%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.33%).

High Dividend: TFX's dividend (0.34%) is low compared to the top 25% of dividend payers in the US market (3.76%).


Stability and Growth of Payments

Stable Dividend: TFX is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: TFX is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: TFX is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TFX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average management tenure


CEO

Liam Kelly (53 yo)

3.08yrs

Tenure

US$6,782,758

Compensation

Mr. Liam J. Kelly has been Chief Executive Officer at Teleflex Incorporated since January 01, 2018 and has been its Director since May 4, 2018. He serves as Director of Colfax Corporation since January 1, ...


CEO Compensation Analysis

Compensation vs Market: Liam's total compensation ($USD6.78M) is below average for companies of similar size in the US market ($USD10.54M).

Compensation vs Earnings: Liam's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Liam Kelly
Chairman3.08yrsUS$6.78m0.026%
$ 4.8m
Thomas Powell
Executive VP & CFO8.92yrsUS$3.30m0.014%
$ 2.5m
Cameron Hicks
Corporate Vice President of Human Resources & Communications7.83yrsUS$1.20m0.014%
$ 2.6m
James Leyden
Senior Advisor0.083yrUS$1.58m0.059%
$ 11.0m
John Deren
VP & Chief Accounting Officer3.75yrsno data0.0020%
$ 379.2k
Timothy Duffy
VP & Chief Information Officer8.33yrsno datano data
Jacob Elguicze
Treasurer & VP of Investor Relationsno datano datano data
Gwen Chapman
Chief Compliance Officer & Corporate VPno datano datano data
Daniel Logue
Corporate VP0.083yrno data0.019%
$ 3.6m
James Ferguson
President & GM of Surgical - Latin Americano datano datano data
Sunny Goh
President of APACno datano datano data
Jay White
Corporate VP & President of Global Commercial0.083yrno datano data

3.4yrs

Average Tenure

50yo

Average Age

Experienced Management: TFX's management team is considered experienced (3.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Liam Kelly
Chairman3.08yrsUS$6.78m0.026%
$ 4.8m
George Babich
Independent Lead Directorno dataUS$291.88k0.023%
$ 4.2m
John Heinmiller
Independent Director2.08yrsUS$420.84k0.0037%
$ 689.6k
Gretchen Frances Haggerty
Independent Director4.42yrsUS$251.46k0.0053%
$ 994.5k
Richard Packer
Independent Director3.75yrsUS$246.46k0.0050%
$ 927.5k
Stuart Randle
Independent Director11.75yrsUS$262.46k0.0054%
$ 1.0m
Andrew Krakauer
Independent Director3.08yrsUS$254.48k0.0040%
$ 736.1k
Stephen Klasko
Independent Director12.75yrsUS$247.54k0.018%
$ 3.4m
Candace Duncan
Independent Director5.75yrsUS$274.13k0.0052%
$ 957.3k

4.1yrs

Average Tenure

65yo

Average Age

Experienced Board: TFX's board of directors are considered experienced (4.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Teleflex Incorporated's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Teleflex Incorporated
  • Ticker: TFX
  • Exchange: NYSE
  • Founded: 1943
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$18.588b
  • Shares outstanding: 46.69m
  • Website: https://www.teleflex.com

Number of Employees


Location

  • Teleflex Incorporated
  • 550 East Swedesford Road
  • Suite 400
  • Wayne
  • Pennsylvania
  • 19087-1603
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TFXNYSE (New York Stock Exchange)YesCommon SharesUSUSDJan 1968
TBHDB (Deutsche Boerse AG)YesCommon SharesDEEURJan 1968
TBHXTRA (XETRA Trading Platform)YesCommon SharesDEEURJan 1968
T1FX34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 10 REPR 1 COMBRBRLJan 2020

Biography

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It prov...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/03/01 23:20
End of Day Share Price2021/03/01 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.